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Bovine leukemia virus (BLV) infection of rabbits is a tractable model system to evaluate vaccination strategies against lymphotropic
retroviruses, which represent a global human health problem. We have previously developed genetically simplified BLV structural gene
vector (SGV) that replicates BLV structural and enzymatic genes independently of BLV regulatory and accessory genes. Results of a 20-
month study in a rabbit model demonstrated that BLV SGV induces an antiviral immunological response and lacks pathogenicity. Here, these
chronically infected-BLV SGV rabbits are assessed in a proof-of-principle study of preventative vaccination against challenge with
pathogenic BLV. This study commences 24 months after BLV SGV inoculation and proceeds for an additional 20 months. The previously
characterized BLV SGV rabbits and age-matched control rabbits were challenged with 1  108 fetal lamb kidney/BLV producer cells. BLV
SGV rabbits seroconverted upon BLV challenge, but did not progress to BLV infection nor clinical disease. By contrast, naive rabbits became
infected and succumbed to lymphotropic disease. Our findings provide proof-of-principle that chronic infection with BLV SGV induces
protection against BLV infection. The data indicate that SGV based on HTLVor HIV is a promising approach against lymphotropic disease
by human retroviruses.
D 2004 Elsevier Inc. All rights reserved.
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Bovine leukemia virus is a complex oncogenic retrovirus
that is genetically related to human T-cell leukemia virus type
1 (HTLV-1) (Sagata et al., 1984). The genomes of these
lymphotropic viruses and human immunodeficiency virus
(HIV-1) encode essential regulatory and accessory proteins in0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: boris-lawrie.1@osu.edu (K. Boris-Lawrie).addition to the Gag, Pol, and Env structural and enzymatic
proteins that are encoded by both simple and complex
retroviruses. Progression to neoplasia by BLV and HTLV is
associated with the virus-encoded regulatory and accessory
proteins, which induce deregulation of lymphocyte homeo-
stasis. Tax regulatory protein is an essential transcriptional
transactivator that functions through the Tax responsive
element (TRE) in the viral U3 promoter. Tax also trans-
activates transcription of a cadre of cellular genes involved in
cell growth control, differentiation, cell cycle control, and
DNA repair processes (Akagi et al., 1996; Armstrong et al.,
1993; Ressler et al., 1997; Trejo et al., 1996; Wano et al.,04) 434–439
V. Altanerova et al. / Virology 329 (2004) 434–439 4351988). Tax is sufficient to induce cellular transformation in
vitro and neoplastic disease in mice (Endo et al., 2002;
Grossman et al., 1995; Nerenberg, 1990; Robek and Ratner,
1999; Ross et al., 1996). Rex regulatory protein functions
through the Rex responsive element (RxRE) in viral genomic
RNA to activate nuclear export of unspliced and singly
spliced transcripts (Heger et al., 1999; Kusuhara et al., 1999).
While Rex is required for efficient viral replication, the
protein does not play a direct role in cellular transformation
(Ye et al., 2003). The BLVand HTLVaccessory genes encode
multifunctional proteins that determine efficient infection of
lymphocytes and maintenance of high proviral loads in
animals, activation of host cells, and regulation of gene
transcription (Albrecht and Lairmore, 2002; Kucerova et al.,
1999; Lefebvre et al., 2002).
Experimental infection of rabbits by inoculation of BLV-
infected cells reproducibly produces persistent infection of
lymphocytes and wasting disease within 20 months and
provides a tractable model to evaluate BLV vaccination
strategies (Altanerova et al., 1989a, 1989b; Wyatt et al.,
1989). We have previously developed a genetically sim-
plified derivative of BLV that replicates independently of
the BLV regulatory and accessory genes and lacks patho-
genicity in rabbits (Boris-Lawrie and Temin, 1995; Boris-
Lawrie et al., 1997). Here, we test the hypothesis that long-
term infection of rabbits with the genetically simplified BLV
can prevent infection by pathogenic BLV.
The simplified BLV derivative is encoded by a BLV
structural gene vector (SGV) that is distinctly different
from classic retroviral vectors. The SGV encodes BLV
Gag, Pol and Env proteins from vector genomic RNA
that contains BLV cis-acting replication sequences for the
express purpose of producing a replication-competent
vector virus (Fig. 1) (Boris-Lawrie and Temin, 1995;
Boris-Lawrie et al., 1997). The BLV SGV lacks most ofFig. 1. Comparison of genomic structures of BLV and BLV SGV with cis-acting
with U3, R, U5 regions labeled. Labeled rectangles, open reading frames; TRE
responsive element; BLV cis-acting replication sequences: att, provirus integration
polypurine tract. (B) BLV SGV. Terminal black boxes, SNV LTRs with U3, R, U
sequence of poliovirus.the BLV long terminal repeat (LTR) sequences, including
the TRE and RxRE. BLV LTR sequences are replaced
with LTRs of spleen necrosis virus (SNV). The con-
stitutive SNV U3 promoter modulates Tax-independent
vector gene expression. Rex/RxRE-independent expres-
sion of hybrid SNV-BLV RNA is attributed to 5V SNV
RU5 sequences, which in other studies have been shown
to facilitate Rev/Rev responsive element (RRE)-independ-
ent expression of unspliced HIV-1 gag-pol RNA (Butsch
et al., 1999). BLV env is positioned downstream of an
internal ribosome entry sequence to facilitate cap-inde-
pendent translation of Env from polycistronic gag-pol-env
genomic RNA. BLV SGV replicates a selectable BLV
vector to a titer similar to BLV in cultured D17
osteosarcoma cells (Boris-Lawrie et al., 1997). The vector
virus is replication-competent in D17 cells and in
peripheral blood mononuclear cells (PBMC) of exper-
imentally infected rats and rabbits (Boris-Lawrie et al.,
1997; Kucerova et al., 1999).
Rabbits have been infected by inoculation with BLV
SGV-producer cells or by in vivo transfection of BLV SGV
proviral DNA (Boris-Lawrie et al., 1997; Kucerova et al.,
1999). The BLV SGV subsequently propagates by reverse
transcription and sequential cycles of error-prone retroviral
replication generate quasi-species of BLV SGVs that have
potential to induce a polytypic immune response against
diverse strains of BLV (Kucerova et al., 1999). Immunoblot
results have verified that BLV SGV infection induces
antibodies against BLV Gag and Env structural proteins in
rats and rabbits, and antiviral seroconversion remained
detectable for 15 months of a 20-month study in rabbits
(Kucerova et al., 1999). Compared to BLV controls, the
BLV SGV rabbits exhibited similar levels of antiviral
antibodies but a proviral load that is lower by a factor of
one-hundred. We speculate that the robust antiviralreplication sequences. (A) BLV genome. Terminal white boxes, BLV LTRs
, Tax responsive element; asterisk, major BLV splice donor; RxRE, Rex-
sequence; E, viral RNA encapsidation signal, PBS, primer binding site; PPT,
5 regions labeled. Shaded rectangle labeled IRES, internal ribosome entry
V. Altanerova et al. / Virology 329 (2004) 434–439436response relative to lower proviral load is attributable to
constitutive expression from the Tax-independent SNV U3
promoter in a small population of activated lymphocytes
(Kucerova et al., 1999). The BLV SGV rabbits lacked any
clinical sign of disease progression for the duration of the
study, whereas all BLV rabbits exhibited opportunistic
infections that culminated in a clinical outcome of death
within a period of 3 to 20 months. Here, we used these
previously characterized BLV SGV rabbits to determine
whether or not chronic infection with BLV SGV induces
protection against challenge with wild type BLV.Results
Challenge with BLV producer cells induces anti-BLV
antibodies
This is a long-term pilot study that commenced at 24
months after infection with BLV SGV with a total duration
of 4 years. At the onset, the BLV SGV rabbits displayed no
clinical symptoms and there were no differences in
hematocrit values between challenged and control rabbits,
which ranged from 0.3 to 0.5 and verified lack of
lymphoproliferation. The BLV SGV rabbits (44-5 and 44-
6) and two age-matched naRve control rabbits (46-3 and 46-
5) were challenged with 1.0  108 BLV-infected fetal lamb
kidney (FLK/BLV) cells, which harbor multiple BLV
proviruses (Altaner et al., 1985). The challenged rabbits
were evaluated at monthly intervals for antiviral antibody
levels by immunoblot, BLV proviral load by PCR and
clinical signs of disease progression.
Challenge with the FLK/BLV cells induced BLV Gag
antiserum in both the BLV SGV rabbits and the age-
matched controls (Table 1). Consistent with our previous
observations (Kucerova et al., 1999), the control BLV-
rabbits sustained anti-Gag antibody levels until they
succumbed to clinical decline. The BLV rabbits BLV
presented with severe weight loss, bronchopneumonia,
diarrhea, abscesses, and leg paralysis. The cause of death
was opportunistic infections due to severe immunodefi-Table 1
Reactivity to BLV Gag in BLV-challenged rabbits
Status Animal no. Level of BLV Gag ant
Month post-challenge
0 1 2
BLV SGV-infected for 24 months 44-5 bMD 3+ 2
44-6 bMD + F
NaRve age-matched control 46-3 bMD 2+ 2
46-5 bMD 2+ 2
a Western immunoblot with alkaline phosphatase detection of BLV-specific antiser
dilution; 1+, detectable at 1:50 dilution; 2+, detectable at 1:500 dilution; 3+, dete
b Rabbit 46-3 died during month 21 of opportunistic infections attributable to im
c NA, not available because death of rabbit at month 3 of opportunistic infectionciency, reminiscent with the outcome of AIDS in HIV-1
infected patients (Altanerova et al., 1989a, 1989b). The
BLV SGV rabbits exhibited diminishing anti-Gag antibody
levels, which became undetectable in rabbit 44-6 at 3
months and rabbit 44-5 after 14 months. The results verified
exposure to BLV in the BLV SGV and control rabbits.
BLV SGV infection protects against BLV infection
PCR assays to assess BLV challenge infection of PBMC
were performed at four sampling points between 1 and 20
months. First, PCR was performed with primers comple-
mentary to BLV pol sequences, which are present in both
the BLV SGV and BLV genome. PCR with primers
complementary to h-actin was used to assess any minor
differences in sample loading. Proviral loads were assessed
in parallel against a dilution series of PBMCs from a BLV-
infected rabbit. BLV SGV rabbit 44-5 displayed low, but
consistently positive signal from 1 to 20 months (Fig. 2). By
comparison to the titration series, the intensity of the
proviral signal is similar to 100 PBMC from a BLV-infected
control. BLV SGV rabbit 44-6 also produced consistently
positive signal from 1 to 20 months and the level of
intensity is similar to 50 PBMC. BLV rabbit 46-3 displayed
a robust signal beginning at 1 month post-challenge and
displayed intensity similar to 50,000 BLV PBMC. Similar to
the trend in BLVantibody level, the proviral load declined in
the sample collected just before death. The signal at 20-
months declined to an intensity similar to 1000 BLV PBMC.
The intensity of the h-actin signal remained similar between
both groups of samples and verified similar sample loading.
A second PCR was performed with primers comple-
mentary to BLV tax sequences, which are present exclu-
sively in the BLV genome. Southern blot analysis with BLV
tax probe was used to verify the specificity of the PCR
product and DNA from BLV-infected rat cell line R(BLV)
provided a positive control for the size of the 1009-bp tax
amplicon (Fig. 3). Beginning at 1 month, BLV tax
sequences were detectable in 50,000 PBMC of BLV rabbit
46-3 (Fig. 3, panel B). The observation of signal from
50,000 PBMC indicates that the sensitivity of the tax andisera
with BLVa
3 6 9 12 14 20
+ 2+ 2+ 1+ 1+ 1+ bMD
bMD bMD bMD bMD bMD bMD
+ 2+ 2+ 2+ 2+ 2+ 1+b
+ NAc NA NA NA NA NA
a. bMD, no visible signal at 1:50 dilution;F, barely detectable signal at 1:50
ctable at 1:5000 dilution.
munodeficiency.
s attributable to immunodeficiency.
Fig. 2. Semi-quantitative PCR analysis of BLV pol detects differences in
proviral load between BLV SGVand BLV-rabbits. PBMC were harvested at
month indicated after challenge with 1  108 FLK/BLV cells from
indicated rabbits that had been infected with BLV SGV for 24 months or
from age-matched naı¨ve controls. DNA from 50,000 PMBC was subjected
to nested PCR and gel electrophoresis and stained with ethidium bromide.
The position of the 591-bp amplicon is designated by the labeled arrow. In
parallel, DNA from 20,000 PBMC was subjected to PCR with primers
complementary to h-actin. The position of the 594-bp amplicon is
designated by the labeled arrow and the signals were quantified by
densitometry.
Fig. 3. BLV tax sequences are not detectable in PBMC of BLV SGV rabbits
after challenge with BLV. DNA from 50,000 PMBC was subjected to PCR
with BLV tax primers and the products were subjected to Southern blot
hybridization with gel-purified radiolabeled tax DNA probe. R(BLV),
positive control DNA from rat cells chronically infected with BLV [100 ng]
(Altanerova et al., 1989a,b). (A) BLV SGV rabbit 44-5 does not exhibit
detectable tax sequences. (B) BLV rabbit 46-3 exhibits tax sequences
beginning one-month post-challenge. (C) BLV SGV rabbit 44-6 does not
exhibit detectable tax sequences. (D) negative control naRve rabbit 46-4
does not exhibit detectable tax sequences.
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were not detectable in equivalent PBMC samples from the
BLV-challenged BLV SGV rabbits (44-5, panel A and 44-6,
panel C) nor from a naive rabbit kept in close proximity of
the challenged animals (46-4, panel D). As summarized in
Table 2, both BLV rabbits consistently exhibited presence of
BLV provirus, whereas tax was not detectable in either BLV
SGV rabbit, despite antiviral seroconversion. The data
indicate that the BLV SGV rabbits do not harbor detectable
BLV provirus and that BLV SGV infection protects against
BLV infection. The BLV SGV rabbits have remained
clinically healthy for longer than 24 months.
A second approach was used to confirm BLV status of
the challenged BLV SGV rabbits. Ten ml of blood from
the BLV SGV rabbits (44-5 and 44-6) was inoculated
intravenously to naRve adult rabbits and PBMC were
harvested and subjected to immunoblot and PCR analysisover a 6-month period. Each recipient rabbit became
seropositive for anti-BLV Gag, positive by PCR for pol
and negative for tax (data not shown). The data verify
the presence of transcriptionally active BLV SGV
provirus in PBMCs and that the vaccinated animals are
protected against BLV infection.Discussion
Infection of bovine with BLV is a barrier to cattle
exportation and infection of humans with HIV-1 and HTLV-
1 represents a global health problem. Therapeutic elimi-
nation of these viral infections is complicated by at least two
hallmark features of the retrovirus lifecycle: permanent
integration of provirus into the genome of infected cells and
capacity to produce genetically diverse progeny. These
features of the replication cycle of retroviruses present
challenges to conventional vaccination strategies and
provide rationale for development of vaccines based on
replication-competent retroviral vector (Boris-Lawrie and
Temin, 1995; Temin, 1993). A preventative vaccine against
BLV infection is a step toward development of a preventa-
tive treatment against human lymphotropic infections. Our
results validate that delivery by in vivo DNA transfection is
Table 2
BLV tax sequences in rabbit PBMCs by PCR and Southern blot hybridization
Status Animal no. Responsea
Month post-challenge with BLV
0 1 2 3 6 9 12 14 20
BLV SGV-infected for 24 months 44-5  NDb     ND ND 
44-6         
NaRve age-matched control 46-3  + + ND + + + + +c
46-5  + + NAd NA NA NA NA NA
a Presence (+) or absence () of positive signal after gene-specific PCR and Southern blot hybridization on DNA from 50,000 PBMC.
b ND, not determined, sample not available for analysis.
c Rabbit 46-3 died during month 21 of opportunistic infections attributable to immunodeficiency.
d NA, not available because death of rabbit at month 3 of opportunistic infections attributable to immunodeficiency.
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infection. Four years after infection, BLV SGV produced
protection against challenge with pathogenic BLV. Cell-
mediated immunity is induced by BLV infection (Gatei
et al., 1993; Kabeya et al., 2001) and replication of BLV
SGV is expected to induce an anti-BLV cell-mediated
immune response that is essential protection against BLV
infection. Another possible explanation for protection
against BLV infection is virus interference. However, this
mechanism would be expected to require a significant
percentage of BLV SGV-positive cells, and this is not
observed in either tissue culture experiments nor in rabbits
(Boris-Lawrie et al., 1997; Kucerova et al., 1999). We
speculate that a small population of PBMC harbor the BLV
SGVand these cells are sufficient to provide immunological
memory of exposure to BLV antigens and elicit a cell-
mediated immune response.
In conclusion, this small but long-term pilot study was a
necessary step in evaluation of SGV as a protective
vaccination approach. We observed that both of the BLV
SGV rabbits, but not the naive control animals, are protected
against BLV infection and disease and that BLV SGV
infection over a 44-month period does not produce collateral
disease. These results provide proof-of-principle that the
SGV is a promising novel live-attenuated virus vaccination
strategy and warrants investigation in a large study
population that provides statistical prediction of protective
efficacy. Furthermore, this study indicates that in vivo
transfection with SGV based on HTLV or HIV-1 is a
promising vaccination approach against human lympho-
tropic disease.Material and methods
Animal procedures
As described previously, BLV SGV infections were
produced in outbred grey Chinchilla rabbits by transfection
with vector DNA (Kucerova et al., 1999). Six-week-old
rabbits were treated with three 50-Ag doses of BLV SGV
provirus pU5gag-pol-env (Boris-Lawrie et al., 1997) byintradermal injection at five sites between the mid-thoracic
and inguinal region of the dorsal side. Blood transfusion
from BLV SGV rabbits to naRve control rabbits was
performed using whole blood (10 ml) and intravenous
inoculation into the central ear vein of adult rabbits. The
rabbits were maintained with unlimited access to food and
water in the approved animal care facility of the Cancer
Research Institute, Slovak Academy of Sciences, Bratislava,
Slovakia.
PCR analysis of PBMC DNA
To prepare peripheral blood mononuclear cell (PBMC)
samples for PCR, PBMCs were isolated by a Ficoll-Paque
(Pharmacia) gradient centrifugation and washed three times
with phosphate buffered saline. Lymphocytes were lysed
with SDS, treated with proteinase K overnight at 37 8C, and
extracted with phenol-chloroform. One microgram of DNA
was combined in a 50-Al PCR mixture with specific primers,
incubated for 1 min at 94 8C, 1 min at 54–62 8C, 1 min at
72 8C for 25–30 cycles, and 10 min at 72 8C. The products
were analyzed on agarose gels. BLV pol primers KB2341
(GAA CGC CTC CAG GCC CTT CAA GA) and KB561
(CAT TGG AGG TCT CCT AAG ACC) amplify a 709-bp
primary PCR product. Aliquots of primary PCR product
were subjected to seminested PCR with BLV pol primers
KB560 (GGA GGT TTG TGC ATG ACC TAC) and
KB561 to amplify a 591-bp PCR sequence. BLV tax
sequences were amplified by nested PCR and detected by
Southern blot hybridization. The primers for the primary
reaction were (sense) AACGACAAAATTATTTCTTGTC
and (antisense) CGGGGCGGTGGCGGCGCCTAG and the
primers for the secondary reaction were (sense) GCAAQ
GTGTTGTTGGTTGG and (antisense) TCAAAAAAGGQ
CGGGAGAGCC. BLV tax-specific PCR products were
detected by Southern blot hybridization to [a32P]-dCTP-
labeled probe that was prepared by PCR using BLV provirus
pBL913 as a template and purified from agarose gels by
QIAEX II Gel Extraction Kit (Qiagen). The probe was
labeled by the random-primer method with Redi-Primek
reagent (Amersham). Hybridization was performed in Rapid
Hybk solution (Amersham) under stringent conditions and
V. Altanerova et al. / Virology 329 (2004) 434–439 439signal detected by autoradiography. Control reactions were
performed with actin primers (Kucerova et al., 1999).
Western immunoblot analysis
As described previously (Boris-Lawrie et al., 1997),
whole BLV was prepared by ultracentrifugation of cell-free
culture supernatants of FLK/BLV cells. Virus proteins were
separated on polyacrylamide gels, transferred to nitro-
cellulose membrane. Membrane strips were subjected to
Western immunoblot analysis with the designated rabbit
sera prepared at various dilutions and positive control serum
was polyspecific anti-BLV rabbit serum. Western blue
stabilized substrate for alkaline phosphatase (Promega)
was used for color development.Acknowledgments
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